Department of Obstetrics and Gynecology, Cruces University Hospital, Baracaldo, Vizcaya, Spain.
J Perinat Med. 2010;38(1):23-8. doi: 10.1515/jpm.2010.010.
To compare the success rate of external cephalic version (ECV) at term using ritodrine or atosiban as a tocolytic agent.
Prospective cohort study with a sample of 236 pregnant women with a breech presentation at term, from November 2006 to March 2008. Data have been analyzed from the moment the cephalic version is performed until the time of delivery.
ECV success rate using ritodrine as a tocolytic agent was 56.8% compared to 31.4% with atosiban. Ritodrine increases the version success potential more significantly than atosiban (P<0.05). In both cases, the use of ECV reduced the rate of cesarean sections, although a higher number of versions are required with atosiban [numbers needed to treat (NNT)=9.08] to avoid a cesarean section compared to ritodrine (NNT=3.41).
Ritodrine seems better than atosiban as tocolytic agent for ECVs.
比较在足月时使用利托君或阿托西班作为保胎药物行外转胎位术（ECV）的成功率。
这是一项前瞻性队列研究，纳入了 2006 年 11 月至 2008 年 3 月期间 236 例臀位足月孕妇，从行 ECV 开始直到分娩时对数据进行分析。
使用利托君作为保胎药物的 ECV 成功率为 56.8%，而使用阿托西班的成功率为 31.4%。与阿托西班相比，利托君更显著地增加了胎位转正的可能性（P<0.05）。在这两种情况下，ECV 的应用均降低了剖宫产率，尽管与利托君（NNT=3.41）相比，使用阿托西班（NNT=9.08）需要更多的 ECV 以避免剖宫产。
利托君似乎比阿托西班更适合作为 ECV 的保胎药物。
